Link Pharma Chem Limited

BSE:524748 Stock Report

Market Cap: ₹160.5m

Link Pharma Chem Past Earnings Performance

Past criteria checks 0/6

Link Pharma Chem's earnings have been declining at an average annual rate of -38%, while the Chemicals industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 0.5% per year.

Key information

-38.0%

Earnings growth rate

-38.1%

EPS growth rate

Chemicals Industry Growth17.7%
Revenue growth rate0.5%
Return on equity-3.0%
Net Margin-1.5%
Last Earnings Update31 Dec 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Link Pharma Chem makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:524748 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 24270-4550
30 Sep 242965560
30 Jun 24309-2550
31 Mar 24299-14550
31 Dec 23312-18580
30 Sep 23331-19580
30 Jun 233501560
31 Mar 233887610
31 Dec 2240811630
30 Sep 2245416630
30 Jun 2251811580
31 Mar 2253619580
31 Dec 2153518540
30 Sep 2149414550
30 Jun 2143112590
31 Mar 2134811560
31 Dec 2029412520
30 Sep 2026812500
30 Jun 2025010490
31 Mar 202559500
31 Dec 192441530
30 Sep 192313620
30 Jun 192467480
31 Mar 192457510
31 Dec 1825013500
30 Sep 1825314540
30 Jun 1822711510
31 Mar 1823511490
31 Dec 1722111430
30 Sep 172135380
30 Jun 171814370
31 Mar 171612370
31 Dec 1616019350
30 Sep 161496350
30 Jun 161305340
31 Mar 161236340
31 Dec 15117-15370
30 Sep 15153-4390
30 Jun 15202-11330
31 Mar 15177-22330
31 Dec 14189-18400
30 Sep 14205-14390
30 Jun 14226-5290
31 Mar 142385370

Quality Earnings: 524748 is currently unprofitable.

Growing Profit Margin: 524748 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 524748 is unprofitable, and losses have increased over the past 5 years at a rate of 38% per year.

Accelerating Growth: Unable to compare 524748's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 524748 is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (12.8%).


Return on Equity

High ROE: 524748 has a negative Return on Equity (-3.04%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/19 23:47
End of Day Share Price 2025/02/19 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Link Pharma Chem Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.